# Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

> **NCT01323751** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ACY-1215

## Key facts

- **NCT ID:** NCT01323751
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2016-12
- **Final completion:** 2016-12-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323751, "Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01323751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*